Reid Trenton Powell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Reid Trenton Powell has a total of 362 co-authors. Here are the top co-authors by number of shared publications:
- Clifford Stephan
Texas A&M Health Center for Translational Cancer Research, Houston, TX 77030, USA
97 shared publications - Yong Sung Park
Texas A&M Health Science Center 3 High-Throughput Research and Screening Center, Center for Translational Cancer Research Institute of Biosciences and Technology, Houston, Texas
58 shared publications - Fan Fan
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
45 shared publications - Jason Roszik
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
45 shared publications - Lee M. Ellis
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
45 shared publications - Rajat Bhattacharya
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
45 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (8) , 1198
Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer
Protein arginine methyltransferase 5 (PRMT5) is a synthetic lethal target in methylthioadenosine phosphorylase-deleted (MTAP-null) cancers. Second-generation methylthioadenosine (MTA)-cooperative PRMT5 inhibitors preferentially target MTAP-null cells while largely sparing MTAP-wildtype (MTAP-WT) cells, thereby improving tumor selectivity over first-generation PRMT5 inhibitors. Despite encouraging efficacy and safety signals in early clinical studies, the modest objective response rates (ORRs) observed with these inhibitors suggest that intrinsic or acquired resistance may limit their clinical benefit. Here, we investigated acquired resistance to the MTA-cooperative PRMT5 inhibitor BMS-986504/MRTX1719 in MTAP-null non-small cell lung cancer (NSCLC) cells and sought to identify therapeutic vulnerabilities that emerge upon resistance. Using multiple in vitro-derived resistant models, we found that acquired resistance was accompanied by cross-resistance to mechanistically distinct PRMT5 inhibitors. Notably, this phenotype was not fully explained by altered PRMT5 activity or changes in MTA levels. High-throughput drug screening of paired sensitive and resistant cells revealed increased sensitivity to MEK inhibitors following acquisition of MRTX1719 resistance in KRAS-wildtype NSCLC cells. Consistently, resistant cells exhibited rewired MAPK-related transcriptional programs. Together, these findings identify MEK inhibition as a reproducible collateral vulnerability associated with acquired MRTX1719 resistance in MTAP-null NSCLC models and support further evaluation of MEK inhibition as a potential treatment-switching strategy following resistance.
- 17 August 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (8) , 1198
Open AccessAcquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer
Protein arginine methyltransferase 5 (PRMT5) is a synthetic lethal target in methylthioadenosine phosphorylase-deleted (MTAP-null) cancers. Second-generation methylthioadenosine (MTA)-cooperative PRMT5 inhibitors preferentially target MTAP-null cells while largely sparing MTAP-wildtype (MTAP-WT) cells, thereby improving tumor selectivity over first-generation PRMT5 inhibitors. Despite encouraging efficacy and safety signals in early clinical studies, the modest objective response rates (ORRs) observed with these inhibitors suggest that intrinsic or acquired resistance may limit their clinical benefit. Here, we investigated acquired resistance to the MTA-cooperative PRMT5 inhibitor BMS-986504/MRTX1719 in MTAP-null non-small cell lung cancer (NSCLC) cells and sought to identify therapeutic vulnerabilities that emerge upon resistance. Using multiple in vitro-derived resistant models, we found that acquired resistance was accompanied by cross-resistance to mechanistically distinct PRMT5 inhibitors. Notably, this phenotype was not fully explained by altered PRMT5 activity or changes in MTA levels. High-throughput drug screening of paired sensitive and resistant cells revealed increased sensitivity to MEK inhibitors following acquisition of MRTX1719 resistance in KRAS-wildtype NSCLC cells. Consistently, resistant cells exhibited rewired MAPK-related transcriptional programs. Together, these findings identify MEK inhibition as a reproducible collateral vulnerability associated with acquired MRTX1719 resistance in MTAP-null NSCLC models and support further evaluation of MEK inhibition as a potential treatment-switching strategy following resistance.
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S1. Unsupervised hierarchical clustering of drug AUC values after filtering for min = 0.2 (blue) and max = 0.7 (red).
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S1. Unsupervised hierarchical clustering of drug AUC values after filtering for min = 0.2 (blue) and max = 0.7 (red).
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S2. Heatmap of the CDK2, CDK7, and CDK9 expression in sarcoma cells from the Cancer Cell Line Encyclopedia (CCLE) database.
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S2. Heatmap of the CDK2, CDK7, and CDK9 expression in sarcoma cells from the Cancer Cell Line Encyclopedia (CCLE) database.
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S2. Top 30 ranking sensitive compound for each cell line
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S2. Top 30 ranking sensitive compound for each cell line
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Supplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Supplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S3. Extraction of intersections from the upset plot (Figure 3). Cell lines are colored according to histology (color scheme from Figure 3).
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S3. Extraction of intersections from the upset plot (Figure 3). Cell lines are colored according to histology (color scheme from Figure 3).
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S3. Loading control for the Western blots in Figure 3 of GAPDH for each of the myxoid liposarcoma cell lines: DDL-221, MLS-401-91, and MLS-1765-92.
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S3. Loading control for the Western blots in Figure 3 of GAPDH for each of the myxoid liposarcoma cell lines: DDL-221, MLS-401-91, and MLS-1765-92.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Many of the >130 World Health Organization–defined sarcoma subtypes are chemoresistant. To identify drug candidates with potential for repurposing in sarcomas with unmet needs, we screened structurally diverse small molecules across 20 sarcoma cell lines of various histologies. The screen included 1,387 compounds from the Custom Clinical Collection, NCI-Approved Oncology Set IV, and Selleck Bioactive Collection. The most effective agents were microtubule inhibitors, aurora kinase inhibitors, and heat shock protein inhibitors. Differential drug sensitivity was observed by sarcoma subtype. Ewing sarcoma, for example, was sensitive to aurora kinases and to TORIN-2 (an mTOR inhibitor). In contrast, myxoid liposarcoma and synovial sarcomas exhibited marked sensitivity to SNS-032, a CDK2/7/9 inhibitor identified by our screen. Interestingly, SNS-032 abrogates the downstream YAP pathway, a known driver pathway in the growth of these histotypes. Therefore, similar drug responses across histologies may indicate shared driver pathways and vulnerabilities.Significance:Sarcoma cells are resistant to most compounds that are currently approved for treating various diseases. Ewing sarcoma cells have distinct sensitivities to aurora kinases that can be explored, whereas myxoid liposarcoma and synovial sarcoma cells share similar drug sensitivity fingerprints that could be exploited in future basket trials.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Many of the >130 World Health Organization–defined sarcoma subtypes are chemoresistant. To identify drug candidates with potential for repurposing in sarcomas with unmet needs, we screened structurally diverse small molecules across 20 sarcoma cell lines of various histologies. The screen included 1,387 compounds from the Custom Clinical Collection, NCI-Approved Oncology Set IV, and Selleck Bioactive Collection. The most effective agents were microtubule inhibitors, aurora kinase inhibitors, and heat shock protein inhibitors. Differential drug sensitivity was observed by sarcoma subtype. Ewing sarcoma, for example, was sensitive to aurora kinases and to TORIN-2 (an mTOR inhibitor). In contrast, myxoid liposarcoma and synovial sarcomas exhibited marked sensitivity to SNS-032, a CDK2/7/9 inhibitor identified by our screen. Interestingly, SNS-032 abrogates the downstream YAP pathway, a known driver pathway in the growth of these histotypes. Therefore, similar drug responses across histologies may indicate shared driver pathways and vulnerabilities.Significance:Sarcoma cells are resistant to most compounds that are currently approved for treating various diseases. Ewing sarcoma cells have distinct sensitivities to aurora kinases that can be explored, whereas myxoid liposarcoma and synovial sarcoma cells share similar drug sensitivity fingerprints that could be exploited in future basket trials.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S2. Top 30 ranking sensitive compound for each cell line
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S2. Top 30 ranking sensitive compound for each cell line
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl Figure 5 from Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells
Animal body weight information.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 5 from Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells
Animal body weight information.